Høgh P, Oturai A, Schreiber K, Blinkenberg M, Jørgensen O S, Ryder L, Paulson O B, Sørensen P S, Knudsen G M
Department of Neurology, The Neuroscience Center, University Hospital of Copenhagen, Rigshospitalet, Copenhagen, Denmark.
Mult Scler. 2000 Aug;6(4):226-30. doi: 10.1177/135245850000600403.
The purpose of this study was to investigate the relation between APOE genotype and Multiple Sclerosis (MS) in a genetically homogeneous population. We examined 240 patients consulting the MS-clinic during a period of 3 years (1996 - 1999). The mean age of the patients was 41.7 years (range 19 - 80 Y, SD 10.0 Y). As a measure of the progression rate (PR) the last registered Expanded Disability Status Scale (EDSS) score was divided by the time span (years) from disease onset until the latest assessment. The APOE genotype was determined from saliva and/or blood samples using PCR-techniques. The prevalence of different APOE genotypes was compared with the allele-distribution in a population of 361 persons from a Danish cross-sectional population study. The frequency of APOE-epsilon 4/epsilon 4 homozygotes was significantly higher in the MS-group as compared to controls (P<0.05, odds ratio: 2.3), whereas the frequency distribution of other genotypes did not differ significantly. The rate of progression was significantly faster in the APOE-epsilon 4/epsilon 4 homozygotes compared to other genotypes in the MS group (P<0.05). This study suggests that the APOE-epsilon 4/epsilon 4 homozygotes have an increased risk of developing MS. MS patients with the APOE-epsilon 4/epsilon 4 allele may also have an increased rate of disease progression. Multiple Sclerosis (2000) 6 226 - 230
本研究的目的是在一个基因同质的人群中调查载脂蛋白E(APOE)基因型与多发性硬化症(MS)之间的关系。我们检查了在3年期间(1996 - 1999年)到MS诊所就诊的240名患者。患者的平均年龄为41.7岁(范围19 - 80岁,标准差10.0岁)。作为进展率(PR)的衡量指标,将最后记录的扩展残疾状态量表(EDSS)评分除以从疾病发作到最新评估的时间跨度(年)。使用PCR技术从唾液和/或血液样本中确定APOE基因型。将不同APOE基因型的患病率与来自丹麦横断面人群研究的361人的群体中的等位基因分布进行比较。与对照组相比,MS组中APOE-ε4/ε4纯合子的频率显著更高(P<0.05,优势比:2.3),而其他基因型的频率分布没有显著差异。与MS组中的其他基因型相比,APOE-ε4/ε4纯合子的进展速度明显更快(P<0.05)。本研究表明,APOE-ε4/ε4纯合子患MS的风险增加。携带APOE-ε4/ε4等位基因的MS患者疾病进展速度也可能加快。《多发性硬化症》(2000年)6 226 - 230